Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
biotech
boston blog main
boston top stories
clinical trials
deals
national top stories
boston
fda
san diego blog main
san diego top stories
san francisco blog main
startups
alexion pharmaceuticals
alnylam pharmaceuticals
autoimmune disorders
drugs
glaxosmithkline
hepatitis b
investing
new york blog main
patisiran
san diego
sanofi
achaogen
adams street partners
akcea therapeutics
allosteric
amyotrophic lateral sclerosis (als)
antibiotics
anylam pharmaceuticals
atlas venture
atopic dermatitis
beijing
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boehringer ingelheim
brace pharma
brii bio
What
disease
8
×
medicines
8
×
drug
new
year
adds
ago
hepatitis
infectious
pharma
pharmaceuticals
potential
research
therapeutics
address
akcea
alliance
allosteric
alnylam
alternative
amyloidosis
approved
areas
attr
autoimmune
available
bacteria
battle
better
biopharma
biosciences
bio’s
brii
business
california
cancer
cancer’s
candidate
caught
causing
Language
unset
Current search:
xconomy.com
×
disease
×
medicines
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections